Abstract  Description  Claims  Drawing  Search report  Cited references 

EP2379586B1   [0011]  [0032] 
WO2016126608A1   [0011] 

Immunosuppressive Activities of Adenosine In Cancer   [0111] 
The Icos/IcosI Pathway is Required for Optimal Antitumor Responses Mediated by Anti-Ctla-4 Therapy   [0111] 
Icos is an Inducible T-Cell Co-Stimulator Structurally and Functionally Related To Cd28   [0111] 
Icos-Ligand, Expressed on Human Endothelial Cells, Costimulates Th1 And Th2 Cytokine Secretion By Memory Cd4+ T Cells   [0111] 
Synergistic Anti-Tumor Efficacy of Immunogenic Adenovirus Oncos-102 (Ad5/3-D24-Gm-Csf) And Standard of Care Chemotherapy in Preclinical Mesothelioma Model   [0111] 
Combination of Immunogenic Oncolytic Adenovirus Oncos-102 With Anti-Pd-1 Pembrolizumab Exhibits Synergistic Antitumor Effect in Humanized A2058 Melanoma Hunog Mouse Model   [0111] 
Adenosine Deaminase Inhibition Suppresses Progression Of 4t1 Murine Breast Cancer by Adenosine Receptor-Dependent Mechanisms   [0111] 
Abstract 1755: Pegylated Adenosine Deaminase (Ada2) Prevents Adenosine-Mediated Increase in Tumor Growth and Improves Antitumor Immune Responses   [0111] 
Immunoregulatory Activity of Adenosine and Its Role in Human Cancer Progression   [0111] 
A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment   [0111]